On February 22, 2013, Cardinal Health, Inc. (the "Company") issued and sold $400 million aggregate principal amount of 1.700% notes due 2018 (the "2018 Notes"), $550 million aggregate principal amount of 3.200% notes due 2023 (the "2023 Notes") and $350 million aggregate principal amount of 4.600% notes due 2043 (the "2043 Notes," and, together with the 2018 Notes and 2023 Notes, the "Notes"). In connection with the sale of the Notes, on February 19, 2013, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Merrill Lynch, Pierce, Fenner & Smith Incorporated, Deutsche Bank Securities Inc. and UBS Securities LLC, as representatives of the underwriters named in Schedule II thereto. The offering is being made pursuant to the Company's effective registration statement on Form S-3 (Registration Statement No. 333-169073) previously filed with the Securities and Exchange Commission (the "Registration Statement"). The foregoing description of the Underwriting Agreement is qualified by reference to the text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1.

The Notes are governed by an Indenture dated as of June 2, 2008 between the Company and The Bank of New York Mellon Trust Company, N.A., formerly known as The Bank of New York Trust Company, N.A. Forms of the 2018 Notes, the 2023 Notes and the 2043 Notes are filed as Exhibits 4.1, 4.2 and 4.3, respectively.

In connection with the issuance of the Notes, Rylan O. Rawlins, Associate General Counsel of the Company, and Shearman & Sterling LLP, counsel to the Company, have delivered opinions to the Company regarding the legality of the Notes upon issuance and sale thereof. A copy of each opinion are filed as Exhibits 5.1 and 5.2, respectively.

The Company incorporates by reference the exhibits filed with this Form 8-K into the Registration Statement.

(d) Exhibits.

Exhibit
Number       Description
1.1          Underwriting Agreement, dated as of February 19, 2013, between
             Cardinal Health, Inc. and Merrill Lynch, Pierce, Fenner & Smith
             Incorporated, Deutsche Bank Securities Inc. and UBS Securities LLC, as
             representatives of the underwriters named in Schedule II thereto.

4.1          Form of 2018 Notes.

4.2          Form of 2023 Notes.

4.3          Form of 2043 Notes.

5.1          Opinion of Rylan O. Rawlins, Associate General Counsel of the Company.

5.2          Opinion of Shearman & Sterling LLP.

23.1         Consent of Rylan O. Rawlins, Associate General Counsel of the Company
             (included in Exhibit 5.1).

23.2         Consent of Shearman & Sterling LLP (included in Exhibit 5.2).